DUBAI, UAE, Feb. 17, 2026 /PRNewswire/ — Oilmar DMCC (“Oilmar”) today announced its 10-year anniversary and the launch of “10 Years. 10 Charities. One Responsibility.” a giving initiative linking each year of the company’s journey to charitable partners and causes aligned to the values and responsibilities underpinning global trade.

Founded in 2015 amid volatile energy markets and geopolitical uncertainty, Oilmar has grown into a global bunker and cargo trading house with 80+ professionals, six trading hubs, and a footprint across three continents. The milestone reflects a decade of disciplined expansion, operational advancement and an enhanced emphasis on governance and long-term trust.

“In moments of calm, any company can appear strong. True strength is revealed in times of adversity, through decisions made both under scrutiny and away from it” said Yusif Mammadov, Owner of Oilmar DMCC. 

“Over the past decade, we have grown through periods of volatility and transformation, but our greatest achievement is not scale, it is our character. As we mark ten years, we choose to honor our journey not through celebration alone, but through meaningful contribution.”

Oilmar’s early years focused on establishing a strong foundation amid challenging market conditions, followed by a period of accelerated growth into a global trading house. In recent years, the company has placed increased emphasis on data-driven trading, enhanced compliance and governance, global risk management, operational excellence and sustainable long-term growth.

To mark its anniversary, Oilmar is highlighting each year of its journey through partnerships with charities and cause areas, including humanitarian response, maritime welfare, medical support and research, hunger relief, sustainability and marine protection. Featured organisations include Emirates Red Crescent, The Mission to Seafarers, IHH Humanitarian Relief, Project CURE, Environmental Defence Fund, Cancer Research UK, World Central Kitchen, International Committee of the Red Cross (ICRC), Direct Relief, and the MSC Foundation.

“Logistics and energy connect the world, but they also have a direct impact on people’s lives,” added Mammadov. “As we look to the next decade, we want success to be defined not only by commercial performance, but by our responsibility to people, communities and the oceans that underpin global trade.”

Oilmar DMCC is a global bunker and cargo trading house founded in 2015. The company operates across three continents with 80+ professionals and six trading hubs, supporting customers and partners across international markets.

SYDNEY and AUCKLAND, New Zealand, Feb. 17, 2026 /PRNewswire/ — Virtual IT Group (VITG) today announced the appointment of Maurice McCarthy as Chief Executive Officer, marking a significant milestone in the company’s next phase of growth across Australia and New Zealand. Virtual IT Group Founder, Christian Pacheco, will transition into the role of Founding Director, continuing to shape Virtual IT Group’s vision for the future, service innovation agenda and M&A strategy.

Virtual IT Group Founding Director, Christian Pacheco said, “Maurice’s appointment followed a comprehensive leadership assessment focused on the evolving needs of clients operating in increasingly complex cyber, regulatory, and AI-enabled environments.”

Pacheco added, “Maurice stood out as a leader with the right combination of client empathy, operational discipline, and modern technology insight. Our clients face mounting pressure from cyber threats, compliance obligations, and rapid AI adoption. Maurice has a deep understanding of the dynamics our clients are faced with on a daily basis, and a clear vision for leadership.” 

Mid-sized organisations across healthcare, financial services, education, and other regulated sectors rely on Virtual IT Group for fit-for-sector, security-led IT, cloud, and modern workplace services. These are supported by a 24/7 ANZ Security Operations Centre (SOC) and a high-touch, always-on service model.

Maurice brings deep experience leading client-focused technology and services organisations through growth, transformation, and operational scale. As CEO, his priorities include enhancing client outcomes, improving service reliability, and responsibly embedding AI across service delivery.

Maurice McCarthy, Virtual IT Group CEO said, “Operational and technology leaders are being asked to move faster with AI while meeting unprecedented cyber and compliance demands. Virtual IT Group combines a 24/7 ANZ SOC, AI-driven ticket resolution, and a friendly, expert help desk for one reason, to give our clients peace of mind so they can focus on their mission. None of this happens without our people, from Level 1 engineers to our most experienced consultants. Together, we’ll build on this foundation and lead Virtual IT Group into its next chapter.”

This appointment reinforces Virtual IT Group’s commitment to being a long-term partner to clients, a place where great people build meaningful careers in managed services and cybersecurity. 

About Virtual IT Group
Virtual IT Group is one of the fastest growing mid-market technology and cybersecurity providers in Australia and New Zealand. With scale, reach, and proven expertise, we deliver end-to-end managed IT and security services making our client’s business systems stronger, safer and simpler every day.  
www.vitg.com.au

LONDON, Feb. 16, 2026 /PRNewswire/ — PEI Group, the leading source of data and intelligence for investment professionals across private markets, today announces that Edouard Tavernier will succeed Tim McLoughlin as Chief Executive Officer, with immediate effect.

Edouard Tavernier, PEI Group CEO

Edouard joins PEI Group from S&P Global, where he most recently served as President of S&P Global Mobility and led the transformation of the business into the leading data and analytics provider to the global automotive industry, with revenues of $1.8 billion in 2025. He brings deep experience of building and scaling information and technology businesses, driving product-led organic growth and executing strategic acquisitions across global markets.

PEI Group has become the largest independent provider of intelligence and connections to the global private-markets community, serving GPs, LPs and service providers alike. PEI Group’s unique combination of proprietary data assets, insight and analysis has delivered sustained growth across private equity, private credit, real estate, infrastructure and secondaries through the company’s stable of high-renewal subscription products and sector-defining events and networks.

Commenting on the transition, Tim said:

“I am immensely proud of what the team at PEI Group has achieved together.  We have built a scale business of powerful reach and influence. PEI ‘s clear purpose is to inform and connect global investment professionals – to enable their success.  It will be exciting to see the next chapter unfold under Edouard’s leadership and I welcome him with great confidence in a Company strongly poised for continued impressive growth.”

Reflecting on his appointment, Edouard commented:

“As private markets continue to grow in scale, complexity and importance, proprietary data and insights have never been more critical. PEI Group plays a vital role in enabling the private markets ecosystem and connecting industry stakeholders, and I am thrilled to join the team to accelerate the development of new products and capabilities for our customers.”

Representing the board, Charles Welham, partner at Bridgepoint, commented: “Edouard brings strategic and leadership capabilities that will be critical to the next stage of PEI Group’s journey, and I am excited to see where he and the team can take the business. I would like to thank Tim for his outstanding leadership and commitment to PEI Group over the past seven years of Bridgepoint ownership.”   

Henry Elkington, Chairman of the board, added: “I am delighted to welcome Edouard to PEI Group.  The continued growth of private markets creates the need for timely data, insights and connections. Edouard’s experience will enable him to accelerate the business, building on the incredible foundations that Tim has delivered.”

Tim McLoughlin will continue to serve on the PEI Board as a non-executive director.

About PEI Group
PEI Group is a leading business intelligence company backed by Bridgepoint Group. Our mission is to connect investment professionals with critical market insights and networking opportunities across global specialized markets. Our 17 premium data and analysis brands support knowledge and decision making for 30,000 investors, managers and service providers. Our five membership networks serve 6,500 members, and we host more than 16,000 guests at 40+ conferences and events around the world.

TORONTO, Feb. 16, 2026 /PRNewswire/ — Today, the originator of New-Style Tea, heytea, officially opened its first Canadian heytea lab at CF Toronto Eaton Centre (TEC), marking a major milestone in its North American expansion following the debut of its overseas heytea lab in New York’s Times Square in early 2025.

As the brand’s most avant-garde retail concept, heytea lab serves as a creative hub for tea innovation, flavor exploration, and aesthetic presentation. The TEC opening introduces the “tea lab” series to Canada for the first time, featuring eight globally exclusive, limited-edition beverages crafted for international markets, anchored in the newly developed Rock Oolong tea base—naturally high in aroma and complexity—and reimagining tea through layered flavor design and textural contrast.

To celebrate the grand opening, heytea partnered with renowned Canadian chef Susur Lee to present a refined fusion of haute cuisine and tea culture. The co-created signature drinks, Rock Oolong Caviar and Rock Oolong Caviar Ice Cream, reinterpret contemporary Chinese tea through contrast and balance, pairing savory caviar with the floral depth of Rock Oolong to deliver a fine-dining-inspired sensory experience. The collaboration reflects heytea’s vision of elevating tea in a broader culinary dialogue.

Designed as an immersive creative showcase, the store transforms the R&D process visually. Displays of raw tea leaves, botanical ingredients, and extraction equipment offer transparency into craftsmanship and invite guests to engage with the story behind every drink.

Since entering Canada with its first Vancouver store in 2023, heytea has expanded strategically across the Vancouver and Toronto metropolitan areas, with the TEC flagship signaling its entry as the first New-Style Tea brand into this premier Canadian shopping landmark. The brand now operates six stores nationwide, supported by a dedicated Toronto distribution center launched in December 2025 to ensure consistent quality and supply chain stability.

Through heytea lab, the brand continues to position tea as a cultural medium, building meaningful connections within Toronto’s diverse community.

About heytea

Founded in 2012, heytea revolutionized traditional bubble tea by committing to natural ingredients and today operates around 4,000 stores across more than 330 cities worldwide, with over 100 locations in Hong Kong SAR, Macau SAR, and overseas markets, including more than 45 in North America. The brand has partnered with global fashion, entertainment, and cultural brands including FENDI, alexanderwang, WICKED, POP MART, and Yayoi Kusama.

4DX and SCREENX Drive 32% Box Office Growth Versus Overall Market’s Forecasted 9.1% Increase

Performance Fueled by Blockbuster Titles Including Avatar: Fire and Ash, Jurassic World Rebirth and How to Train Your Dragon

BURBANK, Calif., Feb. 16, 2026 /PRNewswire/ — CJ 4DPLEX, the world’s leading producer of premium film formats and cinema technologies, today announced exceptional 2025 performance across its premium formats. 4DX and SCREENX together generated $497 million in global box office, delivering 32% year-over-year growth and significantly outperforming the broader theatrical market.

The company’s continued expansion was driven by strong exhibitor demand, premium format adoption, and a robust slate of blockbuster releases that resonated with audiences seeking immersive theatrical experiences. In 2025, CJ 4DPLEX signed 198 new locations with leading exhibitors including AMC, Cinepolis, Cinemark, and Showtime Cinemas. Combined global screen count for 4DX and SCREENX reached 1,245 locations worldwide.

“2025 was a defining year for CJ 4DPLEX as both 4DX and SCREENX delivered extraordinary growth in revenue and global footprint,” said Jun Bang, CEO of CJ 4DPLEX. “Continued expansion across worldwide locations, combined with the sustained outperformance of our formats, demonstrates the strength of premium cinema experiences and the increasing value they bring to our exhibitor partners and the industry as a whole.”

4DX Delivers Record Growth in the U.S. and Globally

4DX delivered standout performance in 2025, generating $81 million in U.S. box office across just 67 screens and $289 million internationally, for a total of $370 million globally, representing 31% year-over-year growth.

The format’s motion seating, environmental effects, and immersive design continued to attract younger moviegoers and event-driven audiences, reinforcing 4DX’s position as a powerful driver of incremental attendance, premium pricing, and higher per-screen averages for exhibitors.

SCREENX Continues Strong Momentum Worldwide

SCREENX also delivered strong growth in 2025, generating $35 million in U.S. box office and $92 million globally, representing a 37% year-over-year increase.

The panoramic, multi-screen format has become an increasingly important premium offering for exhibitors seeking differentiated content experiences, enhanced per-screen performance, and greater flexibility in programming major studio releases.

Strategic Investment in Technology and Content Strengthens Long-Term Growth

In 2025, CJ 4DPLEX materially strengthened its technology and content foundation, positioning SCREENX for accelerated global scale. A key initiative was expanded investment in the company’s Seoul-based VFX business, enabling a significant increase in the number of SCREENX titles produced annually, as well as a meaningful expansion in the number of minutes per film utilizing the full 270-degree format.

At the same time, CJ 4DPLEX completed a comprehensive redesign of the SCREENX technology platform, enhancing image quality, synchronization, calibration, and operational reliability. This next-generation SCREENX system has now been successfully implemented with key strategic partners, including a full deployment across Cinemark’s SCREENX locations and all newly built AMC SCREENX auditoriums, highlighted by AMC’s flagship and highest-performing location in Burbank.

“2025 validated our strategy to invest simultaneously in premium format scale, content capability, and technology,” said Don Savant, CEO of CJ 4DPLEX Americas. “Audiences are clearly choosing premium experiences, and our investments in SCREENX VFX, expanded 270-degree storytelling, and next-generation technology are translating into stronger per-screen performance and repeatable economics for exhibitors. As we enter 2026 with a robust studio slate and growing backlog, we are well positioned to continue outperforming the broader market.”

The result is a structurally stronger technology foundation that materially improves CJ 4DPLEX’s competitive position, enhances exhibitor confidence, and supports long-term profitability as the SCREENX network continues to scale globally.

About CJ 4DPLEX
CJ 4DPLEX is a proud subsidiary of CJ Group, Korea’s leading lifestyle and culture company. Headquartered in Sangam, Seoul, we design and develop immersive cinema technologies that inspire audiences worldwide. Guided by creativity, technology, and cultural vision, we are committed to redefining the future of cinema starting right here in Korea.

CJ 4DPLEX is redefining the moviegoing experience across many countries worldwide, working with the world’s top exhibitors to deliver SCREENX, 4DX and ULTRA 4DX to audiences everywhere. From the United States to Europe, Asia, and the Middle East, our global presence keeps growing driven by our mission to make immersive storytelling the standard in cinema. Innovation drives us to connect people beyond language and borders through shared experiences.

About SCREENX
SCREENX is the world’s most immersive platform, breaking free from the boundaries of a single screen to place audiences at the heart of the story.

With visuals flowing seamlessly across the walls, SCREENX connects film and space, creating moments of true natural immersion. Every sequence is curated to reflect the director’s vision, turning each film into a journey only SCREENX can deliver.

About 4DX
4DX provides the best synesthetic viewing experience that connects the audience with movies through its state-of-the-art motion-seats and 21 environmental effects that include water, wind and scents. The 4DX theater is a special theater where you can feel various environmental effects such as wind, light, fog, fragrance, and vibration, as well as motion chairs that move according to the scene of the movie. Audiences can feel a new level of 4DX effect that maximizes vividness in each scene beyond simply watching movies with limitations of existing video and sound.

CJ 4DPLEX can be found at www.cj4dplex.com.

TULSA, Okla., Feb. 16, 2026 /PRNewswire/ — Zeeco, a global leader in advanced combustion and environmental solutions, today announced the acquisition of Applicot Corporation, a leading Japanese combustion company. This strategic move strengthens Zeeco’s footprint in the Japanese domestic market and enhances local support for Engineering, Procurement, and Construction (EPC) customers throughout the region.

Darton Zink (left) and Susumu Morita shake hands after they finalize the acquisition of Applicot by Zeeco, Inc.

Applicot has operated as an official licensee of Zeeco for more than 35 years. Zeeco’s acquisition of the company combines Applicot’s strong market presence with Zeeco’s global resources, manufacturing infrastructure, and innovative technologies to deliver comprehensive combustion solutions to customers in Japan.

“Bringing Applicot fully into the Zeeco family marks an exciting milestone in our growth strategy,” said Darton Zink, President and CEO of Zeeco. “This acquisition reinforces our commitment to providing localized expertise backed by global capabilities, ensuring our customers receive the highest level of service and support.”

While Applicot’s core business has historically focused on flare systems, Zeeco plans to expand Applicot’s capabilities to include a full range of combustion and environmental solutions, delivering greater value to customers across multiple industries.

“Zeeco has played a trusted and important role in Applicot’s history for decades,” said Susumu Morita, Managing Director of Applicot. “Becoming a fully integrated member of the Zeeco family is a natural progression and one that creates new opportunities for our team and the customers we proudly serve.”

Applicot will remain a trusted brand in Japan as a wholly owned subsidiary of Zeeco. Zeeco’s acquisition of Applicot was finalized on January 13, 2026.

About Zeeco, Inc. 
Founded in 1979, Zeeco has steadily become the world leader in designing and manufacturing advanced combustion and environmental solutions. Headquartered in Tulsa, Oklahoma, USA, Zeeco is a privately held business with more than 3,000 employees and 30+ global locations. The company executes thousands of projects yearly for refining, production, petrochemical, LNG, power, pharmaceutical, biogas, and other industries. ZEECO® products and solutions include ultra-low-NO_x burners, flare systems, thermal oxidizers, vapor control, rentals, aftermarket solutions, global field services, combustion electronics, and process heaters. Zeeco’s comprehensive offering helps customers reduce emissions, optimize processes, and maximize operating efficiency while meeting global environmental compliance requirements. Zeeco also operates the world’s largest combustion research and testing facility, as well as a manufacturing facility, on a 250-acre campus at its Global Technology Center in Broken Arrow, Oklahoma, USA. Learn more at Zeeco.com. 

About Applicot Corporation
Applicot Corporation, a wholly owned subsidiary of Zeeco based in Yokohama, Japan, was founded in 1986 and has maintained a strong relationship with Zeeco for nearly 40 years. For decades, Applicot has supplied combustion equipment for capital projects throughout Japan and beyond. As part of Zeeco, Applicot continues to support customers in Japan and abroad with reliable products and local expertise.

Contact: Mandy Vavrinak
Crossroads Communications
(918) 633-4397
mandy@crossroads-team.com 

Photo – https://laotiantimes.com/wp-content/uploads/2026/02/zeeco_darton_zink_susumu_morita__applicot_closing.jpg

Logo – https://laotiantimes.com/wp-content/uploads/2026/02/zeeco_logo_logo.jpg

HIGHLIGHTS

• Abstract outlining key findings from the Co-PSMA Investigator-Initiated Trial (IIT) has been released.
• The study was led by Prof Louise Emmett at St Vincent’s Hospital Sydney, and the abstract was accepted for oral presentation at the upcoming European Association of Urology (EAU) Congress 2026.
• Co-PSMA IIT evaluated the performance of Clarity’s diagnostic product, ⁶⁴Cu-SAR-bisPSMA, in a head-to-head comparison to standard-of-care (SOC) ⁶⁸Ga-PSMA-11 in 50 patients with biochemical recurrence (BCR) of prostate cancer (with prostate-specific antigen [PSA] 0.2-0.75 ng/mL) following radical prostatectomy who were candidates for curative salvage therapy.
• ⁶⁴Cu-SAR-bisPSMA positron emission tomography (PET) / computed tomography (CT) identified a statistically significant greater number of prostate cancer lesions per patient than ⁶⁸Ga-PSMA-11 PET/CT (study primary endpoint). The mean per-patient lesion was 1.26 for ⁶⁴Cu-SAR-bisPSMA vs. 0.48 for ⁶⁸Ga-PSMA-11, with a difference of 0.78 (95% confidence interval [CI]: 0.52 – 1.04), ratio 2.63 (95%CI: 1.64 – 4.20) (p <0.0001).
• In total, ⁶⁸Ga-PSMA-11 identified 24 lesions across all participants, while ⁶⁴Cu-SAR-bisPSMA next-day imaging detected 63 lesions.
• At a per-patient level, ⁶⁸Ga-PSMA-11 identified 36% (18/50) of trial participants as having a positive scan, while ⁶⁴Cu-SAR-bisPSMA next-day imaging detected prostate cancer in 78% (39/50) of cases.
• Planned patient management changed following assessment of ⁶⁴Cu-SAR-bisPSMA PET/CT in 22/50 (44%) trial participants.
• Further data outlining results from the Co-PSMA IIT will be presented at the EAU Congress 2026.

SYDNEY, Feb. 16, 2026 /PRNewswire/ — Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the release of an abstract on the Co-PSMA (NCT06907641)^[1] IIT, accepted for oral presentation at the upcoming EAU Congress 2026, Europe’s largest urological conference, to be held from 13 to 16 March 2026 in London, UK^[2]. The abstract outlines key findings from the study.

Co-PSMA (“Comparative performance of ⁶⁴Copper [⁶⁴Cu]-SAR-bisPSMA vs. ⁶⁸Ga-PSMA-11 PET CT for the detection of prostate cancer recurrence in the setting of biochemical failure following radical prostatectomy”) was led by Prof Louise Emmett at St Vincent’s Hospital Sydney. This Phase II IIT evaluated the performance of Clarity’s diagnostic product, ⁶⁴Cu-SAR-bisPSMA, in a head-to-head comparison to SOC ⁶⁸Ga-PSMA-11 in 50 prostate cancer patients with BCR who were candidates for curative salvage therapy. Eligible patients were required to have had radical prostatectomy with no salvage therapy and a PSA level between 0.2 and 0.75 ng/mL. ⁶⁸Ga-PSMA-11 PET/CT was followed by ⁶⁴Cu-SAR-bisPSMA PET/CT within 3 weeks (at 1 h and 24 h post-injection, same-day and next-day imaging, respectively), on the same digital PET camera. A standard of truth (SOT) was used to determine accuracy of the PET findings and included biopsy, response to targeted treatment without androgen deprivation therapy [ADT] or corroborative imaging. The primary endpoint of the Co-PSMA study was to assess the difference in mean per patient lesion number.

⁶⁴Cu-SAR-bisPSMA PET/CT identified a statistically significant greater number of lesions per participant than ⁶⁸Ga-PSMA-11 PET/CT, with a higher true positive rate also favouring ⁶⁴Cu-SAR-bisPSMA. The mean per-patient lesion for ⁶⁴Cu-SAR-bisPSMA was 1.26, compared to 0.48 for ⁶⁸Ga-PSMA-11, with a difference of 0.78 (95%CI: 0.52 – 1.04), ratio 2.63 (95%CI: 1.64 – 4.20) (p <0.0001). In total, ⁶⁸Ga-PSMA-11 identified 24 lesions across all participants, while ⁶⁴Cu-SAR-bisPSMA next-day imaging detected 63 lesions. On a per patient level, 36% (18/50) of participants were positive on ⁶⁸Ga-PSMA-11 PET/CT, compared to 78% (39/50) on the ⁶⁴Cu-SAR-bisPSMA PET/CT (next-day imaging). Planned patient management changed following the assessment of the ⁶⁴Cu-SAR-bisPSMA scans in 22/50 (44%) trial participants. Among the participants with an evaluable SOT, the true positive rate was 75% for ⁶⁴Cu-SAR-bisPSMA (21/28) compared to 39% (11/28) for ⁶⁸Ga-PSMA-11.

These results further build on the growing body of evidence showing that ⁶⁴Cu-SAR-bisPSMA improves the detection of prostate cancer, compared to the current SOC prostate-specific membrane antigen (PSMA) PET agents which are known to have low sensitivity, with limited ability to detect cancer, especially in patients with low PSA levels^[3],[4],[5].

Further data outlining results from the Co-PSMA IIT will be announced in mid-March following their oral presentation at the EAU 2026.

Clarity’s Executive Chairperson, Dr Alan Taylor, commented, “The data from the Co-PSMA trial are nothing short of exceptional. We already knew of the significant benefits of the optimised bisPSMA molecule from the early days around 7 years ago, when it was purposely developed to overcome the many shortfalls of the current single-targeting SOC PSMA imaging agents. This innovative benchtop research of the dual-targeting bisPSMA agent quickly progressed to multiple clinical trials, including COBRA^[6], PROPELLER^[7] and SECuRE^[8], which enabled us to secure three Fast Track Designations from the United States (US) Food and Drug Administration (FDA) and advance to two registrational trials, AMPLIFY^[9] and CLARIFY^[10], both of which are nearing completion of recruitment.

“Importantly, in the COBRA trial, we also looked at the performance of ⁶⁴Cu-SAR-bisPSMA in patients with BCR of prostate cancer following definitive therapy, but with participant selection criteria having no limitation on upper PSA levels (median 0.9 ng/mL, range 0.25 to 17.6). The Co-PSMA data we are seeing to date reinforces the COBRA trial findings where more lesions and patients with a positive scan were identified using ⁶⁴Cu-SAR-bisPSMA compared to SOC PSMA PET products, including ⁶⁸Ga-PSMA-11 and ¹⁸F-DCFPyL^[6]. A subset of participants in the COBRA trial had a follow-up SOC PSMA PET. While 90% of these participants had a positive scan on the initial ⁶⁴Cu-SAR-bisPSMA next-day imaging, only 60% were positive on SOC PSMA PET, despite median scan time from the first ⁶⁴Cu-SAR-bisPSMA imaging to the follow-up scan being 73.5 days. The number of lesions across all participants (average sum of lesions across all readers) identified by ⁶⁴Cu-SAR-bisPSMA on next-day imaging was >2.6 times higher than that detected by SOC PET agents (52.6 vs 20 lesions)^[6].

“What we are learning today from the head-to-head Co-PSMA study is a valuable insight into how ⁶⁴Cu-SAR-bisPSMA directly compares against ⁶⁸Ga-PSMA-11, further bolstering the data seen to date. Similar to COBRA, Co-PSMA demonstrated that our product was able to identify more than 2.5 times total number of lesions on the next-day imaging in comparison to the SOC. Furthermore, 4 out of every 5 participants had a positive scan for prostate cancer using ⁶⁴Cu-SAR-bisPSMA, compared to only 2 in 5 participants using ⁶⁸Ga-PSMA-11, therefore making ⁶⁴Cu-SAR-bisPSMA far more reliable than ⁶⁸Ga-PSMA-11 in detecting the presence of cancer in these patients. These findings, coupled with the much higher true positive rate of ⁶⁴Cu-SAR-bisPSMA (75% vs. 39% for ⁶⁸Ga-PSMA-11), will enable clinicians to treat prostate cancer more effectively and with a greater level of confidence based on the accurate detection of disease. These results speak for themselves, clearly illustrating that ⁶⁴Cu-SAR-bisPSMA considerably outperforms its competitors in detecting prostate cancer recurrence. Moreover, this sheds light on the importance of the improved lesion detection, where the diagnostic benefits translate into enhanced patient management: almost half of the Co-PSMA and COBRA study participants had a change of their planned disease management as a result of the ⁶⁴Cu-SAR-bisPSMA findings^[6], which could be absolutely game-changing for clinicians and their patients. This is the difference between allowing prostate cancer lesions to grow or having a clear diagnosis and an active and highly targeted treatment plan. Earlier intervention in BCR can prevent cancer growth and spread, avoid side effects from systemic therapies and considerably improve patient outcomes.

“The current market for PSMA PET imaging in the US alone is around US$2 billion per year, and this is expected to further grow to over US$3 billion by 2029. Unfortunately, this blockbuster market is dominated by ⁶⁸Ga-PSMA-11 and ¹⁸F-DCFPyL, both of which have low sensitivity^[4],[5]. The development pipeline of new products, excluding ⁶⁴Cu-SAR-bisPSMA, offers no significant differentiation from the existing agents, with some new entrants commercialising the unpatented ⁶⁸Ga-PSMA-11 agent, which has been capitalised on by three separate groups already. Time and time again we are seeing significant clinical and logistical benefits offered by ⁶⁴Cu-SAR-bisPSMA through our trials. We strongly believe this product could not only become the new SOC in PSMA PET but also grow the market opportunity further by substantially improving the diagnosis of prostate cancer in many stages of the disease, from its early phases pre-definitive therapy, through to better identification of lesions in the BCR setting, including in patients with oligometastatic disease.

“While the AMPLIFY and CLARIFY trials are key to getting ⁶⁴Cu-SAR-bisPSMA towards commercialisation, Co-PSMA provides further evidence of its benefits to clinicians and prostate cancer patients. This makes the paradigm shift towards improved diagnostics a no-brainer due to our relentless focus on rigorous clinical development and commitment to strong science to change the lives of people living with cancer. The acceptance of the Co-PSMA data by a world-leading urology conference as an oral presentation is a testament to the strength and quality of the data, generated by Prof Emmett, a global key opinion leader in the field.”

Prof Louise Emmett (St Vincent’s Hospital Sydney), Principal Investigator in the Co-PSMA trial, commented, “While approved PSMA PET agents are highly specific, their low sensitivity at low PSA levels means that many patients with early rising PSA show no detectable disease, making treatment planning challenging. More sensitive diagnostics that remain highly specific are needed for effective early intervention in BCR. Our research demonstrates that ⁶⁴Cu-SAR-bisPSMA PET/CT offers a significant advancement in the detection of recurrent prostate cancer. Compared to ⁶⁸Ga-PSMA-11, the 24-hour ⁶⁴Cu-SAR-bisPSMA images identified the site of disease recurrence in a higher proportion of patients, directly informing tailored treatment decisions for men in BCR. These findings highlight the potential for ⁶⁴Cu-SAR-bisPSMA to improve patient outcomes.”

About SAR-bisPSMA

SAR-bisPSMA derives its name from the word “bis”, which reflects a novel approach of connecting two PSMA-targeting agents to Clarity’s proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic that can be used with isotopes of copper-64 (Cu-64 or ⁶⁴Cu) for imaging and copper-67 (Cu-67 or ⁶⁷Cu) for therapy.

Disclaimer

⁶⁴Cu-SAR-bisPSMA is an unregistered product. The safety and efficacy of ⁶⁴Cu-SAR-bisPSMA have not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that this product will become commercially available.

About Prostate Cancer

Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death in men worldwide^[11]. Prostate cancer is the second-leading cause of cancer death in American men. The American Cancer Institute estimates there will be about 333,830 new cases of prostate cancer in the US in 2026 and around 36,320 deaths from the disease^[12].

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers.

www.claritypharmaceuticals.com

References

This announcement has been authorised for release by the Executive Chairperson.